Gut hormone changes the ability of food-related cues to alter dopamine levels

New research findings to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, finds that ghrelin, a natural gut hormone that stimulates feeding, also modulates the ability of tasty food and food-related cues to alter dopamine levels within the striatum, a critical component of the brain's reward system.

Scientists measured dopamine in 'real-time' while rats ate sugar, a highly rewarding food. Administering ghrelin to rats while they ate sugar increased peak dopamine "spikes" within the striatum, whereas administering a drug that blocks ghrelin's actions significantly reduced dopamine levels during sugar intake. Study author Dr. Mitch Roitman (University of Illinois at Chicago) says, "The modulation of brain dopamine reward signals by a gut hormone that regulates appetite strongly supports this interaction as a way to direct the organism's behavior towards further intake, perhaps by making food more rewarding. The results shed light on how peripheral body signals in general can shape brain-directed behavior."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Hormone therapy and puberty blockers alter skeletal size in transgender individuals